PepGen has announced that an independent DSMB has approved the progression to the highest dosage cohort in its Phase II FREEDOM2-DM1 study of PGN-EDODM1.

The post DSMB approves dose escalation in PepGen’s FREEDOM2-DM1 study appeared first on Clinical Trials Arena.